What is the antimicrobial resistance (AMR) profile in Escherichia coli (E. coli)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Antimicrobial resistance (AMR) in Escherichia coli should be managed with empiric therapy guided by local resistance patterns, with nitrofurantoin or trimethoprim-sulfamethoxazole commonly used for uncomplicated urinary tract infections, as recommended by the most recent guidelines 1.

Key Considerations

  • Local resistance patterns should guide empiric therapy, with consideration of regional variability in antimicrobial susceptibility 1.
  • Nitrofurantoin, fosfomycin, and mecillinam have good in vitro activity against E. coli in most regions, making them suitable options for empirical therapy 1.
  • Fluoroquinolones, such as ciprofloxacin, may be used for mild-to-moderate pyelonephritis, but their use should be guided by local resistance patterns and consideration of potential safety issues 1.

Treatment Options

  • Uncomplicated urinary tract infections: nitrofurantoin or trimethoprim-sulfamethoxazole 1.
  • Suspected ESBL E. coli: carbapenems like meropenem or ertapenem may be necessary 1.
  • Pyelonephritis: ceftriaxone or ciprofloxacin may be used, but local resistance patterns should guide therapy 1.

Prevention Strategies

  • Limiting unnecessary antibiotic use 1.
  • Completing full prescribed courses of antibiotics 1.
  • Proper hand hygiene and food safety practices 1.

Mechanisms of Resistance

  • Beta-lactamase production 1.
  • Efflux pumps 1.
  • Plasmid transfer, allowing resistance genes to spread rapidly between bacterial populations 1.

From the Research

Antimicrobial Resistance in E. coli

  • Antimicrobial resistance is a significant concern in E. coli, with increasing resistance rates to various antibiotics over time 2, 3, 4, 5, 6.
  • The most common antibiotics to which E. coli has developed resistance include ampicillin, amoxicillin-clavulanic acid, cefuroxime, ceftriaxone, and co-trimoxazole 2, 3, 4, 5.
  • However, some antibiotics such as nitrofurantoin, gentamicin, and imipenem have been found to be effective against E. coli, including ESBL-producing strains 3, 4, 5.
  • The increasing resistance rates are associated with factors such as age, gender, socioeconomic status, previous community antimicrobial exposure, and multi-morbidity 6.
  • The use of antibiotics in the community, particularly in the elderly population, has been linked to the development of antimicrobial resistance in E. coli 6.

ESBL-Producing E. coli

  • ESBL-producing E. coli strains have been found to be highly resistant to multiple antibiotics, including cephalosporins and fluoroquinolones 3, 4.
  • The prevalence of ESBL-producing E. coli has been increasing over time, with a significant proportion of isolates being multidrug-resistant 3, 4.
  • The effective treatment of ESBL-producing E. coli infections requires the use of antibiotics such as nitrofurantoin, gentamicin, and imipenem 3, 4.

Clinical Epidemiology Characteristics

  • The clinical epidemiology characteristics of urinary tract infections caused by E. coli include high fever, resistance to ampicillin, and sensitivity to amikacin and piperacillin 5.
  • The proportion of E. coli isolates resistant to cotrimoxazole has been increasing over time, highlighting the need for regular monitoring of antimicrobial resistance patterns 5.
  • The use of antibiotics in the community has been linked to the development of antimicrobial resistance in E. coli, emphasizing the need for prudent antibiotic use and antimicrobial stewardship 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.